Fmr LLC Buys 41,882 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Fmr LLC lifted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 25.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 203,510 shares of the company’s stock after acquiring an additional 41,882 shares during the period. Fmr LLC owned 0.07% of Amneal Pharmaceuticals worth $1,693,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Bank of New York Mellon Corp grew its stake in Amneal Pharmaceuticals by 20.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 751,403 shares of the company’s stock worth $4,771,000 after buying an additional 128,772 shares during the last quarter. Acadian Asset Management LLC grew its stake in Amneal Pharmaceuticals by 701.8% during the 2nd quarter. Acadian Asset Management LLC now owns 811,853 shares of the company’s stock worth $5,148,000 after buying an additional 710,598 shares during the last quarter. Jackson Creek Investment Advisors LLC purchased a new position in Amneal Pharmaceuticals during the 2nd quarter worth $1,027,000. Nisa Investment Advisors LLC grew its stake in Amneal Pharmaceuticals by 3,279.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 228,917 shares of the company’s stock worth $1,454,000 after buying an additional 222,144 shares during the last quarter. Finally, Rubric Capital Management LP grew its stake in Amneal Pharmaceuticals by 12.4% during the 2nd quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company’s stock worth $68,083,000 after buying an additional 1,179,830 shares during the last quarter. 31.82% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

AMRX has been the topic of several research analyst reports. Truist Financial boosted their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, October 2nd. Piper Sandler boosted their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target on the stock in a research note on Friday, September 6th. Finally, StockNews.com upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 11th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Stock Performance

Amneal Pharmaceuticals stock opened at $7.83 on Monday. The business’s 50-day simple moving average is $8.49 and its two-hundred day simple moving average is $7.91. The company has a market cap of $2.43 billion, a PE ratio of -11.51 and a beta of 1.12. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $4.74 and a fifty-two week high of $9.48.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, SVP Jason B. Daly sold 43,657 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the completion of the transaction, the senior vice president now owns 13,665 shares of the company’s stock, valued at $117,655.65. The trade was a 76.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 26.56% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.